Immunogenicity

Comprehensive immunogenicity testing services from Synexa covering ADA, NAb and cellular immune responses across all clinical phases.

Immunogenicity Testing Services

Synexa provides comprehensive immunogenicity testing services across all major laboratory sites, supporting programmes from preclinical development through to late-phase clinical trials.

Our expertise spans both humoral (antibody-mediated) and cellular immune responses, with proven excellence in regulated bioanalysis for biologics, vaccines, cell and gene therapies, and novel modalities, across a wide range of matrices including serum, plasma, CSF, saliva, dried blood spots (DBS), and tissue samples.

Scientist using pipette in laboratory

Immunogenicity Assays

High Sensitivity

Anti-Drug Antibody (ADA) and Neutralising Antibody (NAb) Assays

We offer a full tiered anti-drug antibody (ADA) testing strategy, including screening, confirmation, titration, and neutralising antibody (NAb) characterisation. Our NAb assays are available in:

  • Ligand-binding formats (ECL, ELISA, Gyrolab)
  • Cell-based functional assays for accurate biological response measurement
Custom Assay Development

Cellular Immunogenicity Testing

Our advanced cellular immunogenicity assays enable in-depth profiling of T-cell responses:

  • ELISpot and FluoroSpot assays
  • Flow cytometry and intracellular cytokine staining (ICS)

Multiplexed Humoral Response Analysis

We provide detailed analysis of immune responses through:

  • Isotype and subclass-specific detection (IgG, IgM, IgA)
  • Multiplexed platforms including MSD, ELISA, and Gyrolab

Immunogenicity Platforms

We utilise a suite of advanced immunoassay technologies – including MSD, ELISA, Gyrolab, cell-based assays, flow cytometry, and RIA—to deliver sensitive, high-throughput, and functionally relevant immunogenicity data across diverse therapeutic modalities.

More on Immunogenicity

From Detection to Decision: Risk-Based Immunogenicity Testing

Immunogenicity describes treatment‑induced B‑ and T‑cell responses to therapeutics and represents a major hurdle for drug development, due to the…

Immunogenicity 101: Antidrug Antibodies, Neutralising Antibodies, and everything in between

Protein-based biotherapeutic/biologic agents, such as fusion proteins and monoclonal antibodies (mAb) have become the treatment of choice for many indications…

Improving the quality of human health

Contact us

Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline